MedTrace Logo

Tarceva Italian Lung Optimization tRial

NCT00637910 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 850

Last updated 2012-02-24

No results posted yet for this study

Summary

The aim of this study is to assess the superiority of docetaxel in comparison to erlotinib in second line in wild-type EGFR tumour patients.

Conditions

  • Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Erlotinib

Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops

DRUG

Docetaxel

Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). \_Until disease progression or unacceptable toxicity develops

Sponsors & Collaborators

  • Mario Negri Institute for Pharmacological Research

    collaborator OTHER

  • Niguarda Hospital

    collaborator OTHER

  • Fatebenefratelli and Ophthalmic Hospital

    lead OTHER

Principal Investigators

  • Alberto Scanni, MD · Fatebenefratelli and Ophthalmic Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2012-02-29
Completion
2013-02-28

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00637910 on ClinicalTrials.gov